Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.
2.

More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.

Ajiboye S, Sissung TM, Sharifi N, Figg WD.

BJU Int. 2010 Apr;105(7):913-6. doi: 10.1111/j.1464-410X.2009.08999.x. Epub 2010 Jan 8. Review.

3.

Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A.

Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, López-Casillas F.

J Biol Chem. 2001 May 4;276(18):14588-96. Epub 2001 Feb 5.

4.

Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan.

Farnworth PG, Wang Y, Escalona R, Leembruggen P, Ooi GT, Findlay JK.

Endocrinology. 2007 Nov;148(11):5355-68. Epub 2007 Jul 26.

PMID:
17656464
5.

Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma.

Royuela M, De Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R.

Growth Factors. 1998;16(2):101-10.

PMID:
9932228
6.

Betaglycan: a multifunctional accessory.

Bilandzic M, Stenvers KL.

Mol Cell Endocrinol. 2011 Jun 6;339(1-2):180-9. doi: 10.1016/j.mce.2011.04.014. Epub 2011 Apr 28. Review.

PMID:
21550381
8.

Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-β, and extracellular matrix down-regulation.

Coulson-Thomas VJ, Gesteira TF, Coulson-Thomas YM, Vicente CM, Tersariol IL, Nader HB, Toma L.

Exp Cell Res. 2010 Nov 15;316(19):3207-26. doi: 10.1016/j.yexcr.2010.08.005. Epub 2010 Aug 18.

PMID:
20727350
9.

Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.

Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W.

Nature. 2000 Mar 23;404(6776):411-4.

PMID:
10746731
10.
11.

TGFBR3 loss and consequences in prostate cancer.

Sharifi N, Hurt EM, Kawasaki BT, Farrar WL.

Prostate. 2007 Feb 15;67(3):301-11.

PMID:
17192875
12.

The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.

Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC.

Cancer Res. 2007 Feb 1;67(3):1090-8.

13.

Inhibin: actions and signalling.

Phillips DJ, Woodruff TK.

Growth Factors. 2004 Mar;22(1):13-8. Review.

PMID:
15176454
14.

Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.

Bilandzic M, Chu S, Farnworth PG, Harrison C, Nicholls P, Wang Y, Escalona RM, Fuller PJ, Findlay JK, Stenvers KL.

Mol Endocrinol. 2009 Apr;23(4):539-48. doi: 10.1210/me.2008-0300. Epub 2009 Jan 22.

PMID:
19164448
15.

Loss of betaglycan expression in ovarian cancer: role in motility and invasion.

Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC.

Cancer Res. 2007 Jun 1;67(11):5231-8. Epub 2007 May 23.

16.
17.

TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity.

Barrack ER.

Prostate. 1997 Apr 1;31(1):61-70. Review.

PMID:
9108888
18.

Cancer progression: is inhibin alpha from Venus or Mars?

Ball EM, Mellor SL, Risbridger GP.

Cytokine Growth Factor Rev. 2004 Oct;15(5):291-6. Review.

PMID:
15450247
19.

Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.

Matise LA, Palmer TD, Ashby WJ, Nashabi A, Chytil A, Aakre M, Pickup MW, Gorska AE, Zijlstra A, Moses HL.

Breast Cancer Res. 2012 Jul 2;14(4):R98. doi: 10.1186/bcr3217.

20.

Supplemental Content

Support Center